Evidence map›Paper›PMID 32990741›Full record

ArticleJAMA network open2020

Use of Steroid Profiling Combined With Machine Learning for Identification and Subtype Classification in Primary Aldosteronism.

Graeme Eisenhofer, Claudio Durán, Carlo Vittorio Cannistraci, Mirko Peitzsch, Tracy Ann Williams, Anna Riester, Jacopo Burrello, Fabrizio Buffolo, Aleksander Prejbisz, Felix Beuschlein and 4 more

Registry-linked trialAbstract read
In one paragraph

Article in JAMA network open, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06941116 (Steroids-Based Screening for Primary Aldosteronism), which is not on this map. Cited by 54 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06941116 recruitingnot on this mapstarted 2025, after this paper: background citation

Steroids-Based Screening for Primary Aldosteronism

TypeobservationalSponsorQifu LiRan2025 to 2026Enrolled406ConditionsPrimary Aldosteronism, HypertensionArmsSteroid-Based Screening (LC-MS/MS)
3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Primary aldosteronism.Nature reviews. Disease primers · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Approach to the Patient With Primary Aldosteronism: Role of Molecular Imaging.The Journal of clinical endocrinology and metabolism · 2025
    Review
  13. Article
  14. Article
  15. Article
  16. Adrenal Vein Sampling in Primary Aldosteronism-Is The Gold Standard Losing Its Luster?The Journal of clinical endocrinology and metabolism · 2025
    Article
  17. Article
  18. Article
  19. Characterizing the Origins of Primary Aldosteronism.Hypertension (Dallas, Tex. : 1979) · 2025
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Graeme EisenhoferDepartment of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Claudio DuránBiomedical Cybernetics Group, Biotechnology Center, Center for Molecular and Cellular Bioengineering, Center for Systems Biology Dresden, Department of Physics, Technische Universität Dresden, Dresden, Germany.
Carlo Vittorio CannistraciBiomedical Cybernetics Group, Biotechnology Center, Center for Molecular and Cellular Bioengineering, Center for Systems Biology Dresden, Department of Physics, Technische Universität Dresden, Dresden, Germany.
Mirko PeitzschInstitute of Clinical Chemistry and Laboratory Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Tracy Ann WilliamsDivision of Internal Medicine and Hypertension, Department of Medical Sciences, University of Turin, Turin, Italy.
Anna RiesterMedizinische Klinik und Poliklinik IV, Klinikum der Ludwig-Maximilians-Universität München, Munich, Germany.
Jacopo BurrelloDivision of Internal Medicine and Hypertension, Department of Medical Sciences, University of Turin, Turin, Italy.
Fabrizio BuffoloDivision of Internal Medicine and Hypertension, Department of Medical Sciences, University of Turin, Turin, Italy.
Aleksander PrejbiszDepartment of Hypertension, Institute of Cardiology, Warsaw, Poland.
Felix BeuschleinMedizinische Klinik und Poliklinik IV, Klinikum der Ludwig-Maximilians-Universität München, Munich, Germany.
Andrzej JanuszewiczDepartment of Hypertension, Institute of Cardiology, Warsaw, Poland.
Paolo MulateroDivision of Internal Medicine and Hypertension, Department of Medical Sciences, University of Turin, Turin, Italy.
Jacques W M LendersDepartment of Internal Medicine III, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
Martin ReinckeMedizinische Klinik und Poliklinik IV, Klinikum der Ludwig-Maximilians-Universität München, Munich, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Most patients with primary aldosteronism, a major cause of secondary hypertension, are not identified or appropriately treated because of difficulties in diagnosis and subtype classification. Applications of artificial intelligence combined with mass spectrometry-based steroid profiling could address this problem. Objective: To assess whether plasma steroid profiling combined with machine learning might facilitate diagnosis and treatment stratification of primary aldosteronism, particularly for patients with unilateral adenomas due to pathogenic KCNJ5 sequence variants. Design, Setting, and Participants: This diagnostic study was conducted at multiple tertiary care referral centers. Steroid profiles were measured from June 2013 to March 2017 in 462 patients tested for primary aldosteronism and 201 patients with hypertension. Data analyses were performed from September 2018 to August 2019. Main Outcomes and Measures: The aldosterone to renin ratio and saline infusion tests were used to diagnose primary aldosteronism. Subtyping was done by adrenal venous sampling and follow-up of patients who underwent adrenalectomy. Statistical tests and machine-learning algorithms were applied to plasma steroid profiles. Areas under receiver operating characteristic curves, sensitivity, specificity, and other diagnostic performance measures were calculated. Results: Primary aldosteronism was confirmed in 273 patients (165 men [60%]; mean [SD] age, 51 [10] years), including 134 with bilateral disease and 139 with unilateral adenomas (58 with and 81 without somatic KCNJ5 sequence variants). Plasma steroid profiles varied according to disease subtype and were particularly distinctive in patients with adenomas due to KCNJ5 variants, who showed better rates of biochemical cure after adrenalectomy than other patients. Among patients tested for primary aldosteronism, a selection of 8 steroids in combination with the aldosterone to renin ratio showed improved effectiveness for diagnosis over either strategy alone. In contrast, the steroid profile alone showed superior performance over the aldosterone to renin ratio for identifying unilateral disease, particularly adenomas due to KCNJ5 variants. Among 632 patients included in the analysis, machine learning-designed combinatorial marker profiles of 7 steroids alone both predicted primary aldosteronism in 1 step and subtyped patients with unilateral adenomas due to KCNJ5 variants at diagnostic sensitivities of 69% (95% CI, 68%-71%) and 85% (95% CI, 81%-88%), respectively, and at specificities of 94% (95% CI, 93%-94%) and 97% (95% CI, 97%-98%), respectively. The validation series yielded comparable diagnostic performance. Conclusions and Relevance: Machine learning-designed combinatorial plasma steroid profiles may facilitate both screening for primary aldosteronism and identification of patients with unilateral adenomas due to pathogenic KCNJ5 variants, who are most likely to show benefit from surgical intervention.

Indexed as

AdultFemaleHumansHyperaldosteronismMachine LearningMaleMiddle AgedPolandSteroidsSteroids

Identifiers

PMID32990741
PMCPMC7525346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.